Stocks to Watch: Innovation, Expansion, and Breakout Biotech Catalysts

DENVER, Colo., Jul 09, 2025 (247marketnews.com)- Evoke Pharma (NASDAQ:EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in treating patients with moderate to severe gastroparesis, a chronic gastrointestinal disorder. The patent allowance further solidifies GIMOTI’s intellectual property moat and strengthens Evoke’s commercial position. With gastroparesis impacting millions and treatment options limited, this development could enhance revenue durability and attract potential commercial partnerships.

Venu (NYSE:VENU) continues its aggressive growth push with the formal launch of a new Growth and Strategy division, headed by former Live Nation SVP Terri Liebler. The move comes as Venu executes its two-facilities-per-quarter rollout plan and sets sights on $200 million in luxury suite sales for 2025. With a fan-first, asset-backed ownership model and a clear strategy to scale via public-private partnerships and real estate-driven growth, VENU is fast emerging as a disruptor in the live entertainment infrastructure space.

Kazia Therapeutics (NASDAQ:KZIA) shares are in focus after reporting early but promising data from its ongoing Phase 1b trial evaluating Paxalisib in combination with pembrolizumab (Keytruda) and chemotherapy for metastatic triple-negative breast cancer (TNBC). TNBC remains one of the most aggressive and underserved breast cancer subtypes. Early efficacy from the first patient is encouraging and positions KZIA as a potential player in a highly competitive oncology space. Further updates could serve as meaningful inflection points.

Siyata Mobile (NASDAQ:SYTA) is on the verge of a game-changing transformation, awaiting final Nasdaq approval for its $185 million merger with Core Gaming. The move catapults SYTA into the booming $28 billion AI gaming market, a major departure from its legacy communications hardware focus. Core Gaming brings serious credentials: 2,100 titles, 790 million downloads, and 43 million monthly active users, largely driven by its AI-powered COMIC app. This is a bold pivot, and investors appear to be betting on the company’s ability to rebrand as a major digital entertainment player.

ProKidney (NASDAQ:PROK) surged this week after releasing statistically significant and clinically meaningful topline results from its Phase 2 REGEN-007 trial, targeting chronic kidney disease (CKD) in diabetic patients. Lead candidate rilparencel demonstrated strong preservation of kidney function, and with an FDA Type B meeting upcoming to potentially validate eGFR slope as a surrogate for accelerated approval, the stakes are high. Coupled with its RMAT designation, PROK is quickly becoming a front-runner in the regenerative nephrology space. Watch for updates from the ongoing Phase 3 PROACT 1 trial.

Hong Kong-based SU Group Holdings (NASDAQ:SUGP) made headlines with the largest contract in its history, a HK$88.5 million (US$11.3 million) award in the engineering security space. As geopolitical and corporate security concerns rise across Asia, this win could mark the start of a new growth era for the company. Investors may want to monitor SUGP for further contract wins and potential regional expansion.

Sharplink Gaming (NASDAQ:SBET) continues to ride a wave of investor interest following recent integration news involving Ethereum ($ETH). The move potentially expands Sharplink’s footprint in blockchain-enabled gaming and wagering infrastructure, a frontier sector within the sports betting landscape. Look for confirmation on product rollouts and monetization efforts in the weeks ahead.

Also on the Radar

Calidi Biotherapeutics (NASDAQ:CLDI), Basel Medical (NASDAQ:BMGL), and GameSquare Holdings (NASDAQ:GAME).

For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/ or go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SYTA, PROK, VENU, EVOK, KZIA, SUGP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.